The first FDA-approved MASH drug doesn’t treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients in this most advanced stage of the fatty liver disease.
Pharmaceutical companies use Feel Therapeutics’ technology to monitor the mental state of participants in clinical trials of behavioral medications. But the startup envisions its technology eventually also finding a place as a part of clinical care.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Diagonal Therapeutics develops agonist antibodies to treat rare cardiovascular conditions. Using artificial intelligence, the startup’s technology sorts through billions of antibody/receptor combinations to identify the ones that reactivate signaling pathways lost to disease.
AI is meant to have a synergistic relationship with clinicians rather than replace them, pointed out David McSwain, chief medical information officer at UNC Health, during an interview at HIMSS24. In his view, both humans and AI are fallible, but their errors are usually of a different type — so both should be working together to reduce the overall error rate.
During an interview this month at HIMSS24, David Vawdrey — Geisinger’s chief data and informatics officer — said health systems should spend more time designing their plan for evaluating success when it comes to tech pilots.
Lack of automation is the top challenge facing commercialization teams, according to a survey of executives at U.S.-based pharma companies. The survey was conducted in late 2023 and results were reported this month.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Health systems aren’t seeing a ton of ROI when it comes to their AI investments quite yet, as use of the technology is still in an iterative stage. However, Mount Sinai CEO Brendan Carr thinks that is likely to change in the next couple years.
Exscientia’s termination of CEO Andrew Hopkins is for cause and effective immediately. Grounds for termination include misconduct or behavior that brings Hopkins or the company into disrepute, according to his employment agreement.
AI refines KOL (key opinion leader) outreach by quickly uncovering the intricate details of individual thought leaders. AI tools can analyze preferences, behaviors, and interests, equipping MSLs (medical science liaisons) with a comprehensive understanding of each individual KOL.
When it comes to AI, the consensus is that healthcare organizations have an opportunity right now to take an enterprise-wide approach that encompasses everything from workforce to infrastructure to governance and beyond. Here are these ten essential elements of an enterprise-wide AI strategy for healthcare organizations.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
During a panel discussion at CES 2024, health executives shared safe ways AI can be used to support value-based care. This includes automating tasks and predicting who needs additional care.
As we look into the future, 2024 promises a profound transformation. Here are five areas of focus for the upcoming year.
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.
At RSNA, three major trends stood out: the integration of artificial intelligence (AI), a renewed focus on health equity, and a dedicated effort to enhance the patient experience.
Last week, HHS finalized a new rule that requires healthcare AI developers to provide more data about their products to customers, which could aid providers in determining AI tools’ risks and effectiveness. Some AI leaders believe the new guardrails are a step in the right direction, and others are skeptical about whether the new rules are necessary or will be effective.